# BIRC5

Source: https://onco.cc/targets/birc5/  
OnCo record `birc5` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BIRC5 (Baculoviral IAP repeat-containing protein 5) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer and HER2-positive breast cancer.

## Summary

Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localisation of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organisation of the centre spindle by associating with polymerised microtubules.

CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Trastuzumab, Platinum Compound and Taxane Compound.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: baculoviral IAP repeat containing 5; Baculoviral IAP repeat-containing protein 5; EPR-1; survivin; API4
- Tags: cancer-genes-wave
- Symbol: BIRC5
- Class: transcription
- Biology: Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localisation of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organisation of the centre spindle by associating with polymerised microtubules. Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May counteract a default induction of apoptosis in G2/M phase. Location: Cytoplasm; Nucleus; Chromosome; Chromosome, centromere (UniProt). Locus 17q25.3 (HGNC).
- Where found: Non-small-cell lung cancer: CIViC evidence names this disease; HER2-positive breast cancer: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:593: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:593
- UniProt O15392: https://www.uniprot.org/uniprotkb/O15392/entry
- NCBI Gene 332: https://www.ncbi.nlm.nih.gov/gene/332
- Ensembl ENSG00000089685: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000089685

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/birc5.json